Conversely, neoadjuvant androgen deprivation therapy may reduce the number of CD8+ TILs, with a trend toward decreased PD-L1 expression by PC tumor cells (compared with untreated tumors: 7% vs. 21%) [75]. The gene discussed is CD8A; the disease is neoplasm.